BSR_04_0128_A4_S78
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.370
- ESTROGEN_RESPONSE_EARLY+0.300
- WNT_BETA_CATENIN_SIGNALING+0.280
- ANGIOGENESIS+0.270
- OXIDATIVE_PHOSPHORYLATION+0.240
- ESTROGEN_RESPONSE_LATE+0.230
- NOTCH_SIGNALING+0.220
- BILE_ACID_METABOLISM+0.200
- MYOGENESIS+0.190
- COAGULATION+0.130
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.480
- MYC_TARGETS_V2-0.400
- IL6_JAK_STAT3_SIGNALING-0.390
- INFLAMMATORY_RESPONSE-0.390
- TNFA_SIGNALING_VIA_NFKB-0.350
- PI3K_AKT_MTOR_SIGNALING-0.290
- INTERFERON_GAMMA_RESPONSE-0.260
- MTORC1_SIGNALING-0.250
- KRAS_SIGNALING_UP-0.240
- UNFOLDED_PROTEIN_RESPONSE-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4e06764d-9cf1-4cff-ad67-4c5e472fbff5 | — | — | 0.752 |
| 2 | TCGA-CV-7414-01A-11R-2081-07 | — | — | 0.736 |
| 3 | SRR35579826 | — | B | 0.730 |
| 4 | TCGA-IQ-7631-01A-11R-2081-07 | — | — | 0.717 |
| 5 | SRR25617843 | — | B | 0.713 |
| 6 | TCGA-CV-6937-01A-11R-2016-07 | — | — | 0.712 |
| 7 | BS_AD4JPN9Q | Ganglioglioma | — | 0.700 |
| 8 | TCGA-E2-A1BD-01A-11R-A12P-07 | — | B | 0.694 |
| 9 | sclcCHTN02019_S70.txt | — | cohortSC | 0.691 |
| 10 | TCGA-78-7149-01A-11R-2039-07 | — | cohortA2 | 0.691 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |